Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1

10 Mar 2009

Abstract excerpt

To evaluate the effect of deferasirox in human myeloid leukemia cells, and to identify the molecular pathways responsible for antiproliferative effects on leukemia cells during chelation therapy, we performed gene expression profiling to focus on the pathway involved in the anticancer effect of deferasirox. The inhibitory concentration (IC50) of deferasirox was 17-50 microM in three human myeloid cell lines...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to RNA modifications and cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 19298223
DOI: 10.1111/j.1349-7006.2009.01131.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1PMID 19298223Read ↗

Transcriptomic Signature and PROTAC Strategy Revealed Histone Lysine Demethylase as a Target of Anticancer Activity of DeferiproneSemantic proximity Read ↗

Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic CellsSemantic proximity Read ↗

Nutritional Sensor REDD1 in Cancer and Inflammation: Friend or Foe?Semantic proximity Read ↗

UFD1 contributes to MYC-mediated leukemia aggressiveness through suppression of the proapoptotic unfolded protein responseSemantic proximity Read ↗

New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of CancerSemantic proximity Read ↗

Iron Drives Anabolic Metabolism Through Active Histone Demethylation and mTORC1Semantic proximity Read ↗

Deferasirox, an iron chelator, impacts myeloid differentiation by modulating NF ‐ kB activity via mitochondrial ROSSemantic proximity Read ↗

Growth Control Under Stress: mTOR Regulation through the REDD1-TSC PathwaySemantic proximity Read ↗

Inhibition of pyrimidine biosynthesis targets protein translation in acute myeloid leukemiaSemantic proximity Read ↗

Identification and targeting of novel CDK9 complexes in acute myeloid leukemiaSemantic proximity Read ↗

The Clinically Used Iron Chelator Deferasirox is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone DemethylasesSemantic proximity Read ↗

LEDGF/p75 has increased expression in blasts from chemotherapy-resistant human acute myelogenic leukemia patients and protects leukemia cells from apoptosis in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.